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ABSTRACT
Objective: To identify information priorities for
consumers and clinicians making depression treatment
decisions and assess shared decision-making (SDM) in
routine depression care.
Design: 20 questions related to common features of
depression treatments were provided. Participants were
initially asked to select which features were important,
and in a second stage they were asked to rank their
top 5 ‘important features’ in order of importance.
Clinicians were asked to provide rankings according to
both consumer and clinician perspectives. Consumers
completed CollaboRATE, a measure of SDM. Multiple
logistic regression analysis identified consumer
characteristics associated with CollaboRATE scores.
Setting: Online cross-sectional surveys fielded in
September to December 2014.
Participants: We administered surveys to
convenience samples of US adults with depression and
clinicians who treat depression. Consumer sampling
was targeted to reflect age, gender and educational
attainment of adults with depression in the USA.
Primary outcome measures: Information priority
rankings; CollaboRATE, a 3-item consumer-reported
measure of SDM.
Results: 972 consumers and 244 clinicians
completed the surveys. The highest ranked question for
both consumers and clinicians was ‘Will the treatment
work?’ Clinicians were aware of consumers’ priorities,
yet did not always prioritise that information
themselves, particularly insurance coverage and cost of
treatment. Only 18% of consumers reported high levels
of SDM. Working with a psychiatrist (OR 1.87; 95% CI
1.07 to 3.26) and female gender (OR 2.04; 95% CI
1.25 to 3.34) were associated with top CollaboRATE
scores.
Conclusions: While clinicians know what information
is important to consumers making depression
treatment decisions, they do not always address these
concerns. This mismatch, coupled with low SDM,
adversely affects the quality of depression care.
Development of a decision support intervention based
on our findings can improve levels of SDM and provide
clinicians and consumers with a tool to address the
existing misalignment in information priorities.
INTRODUCTION
Treatments for individuals with depression
are numerous, with multiple generations of
antidepressant medications and psychosocial
interventions such as cognitive-behavioral
and problem-solving therapies now delivered
both in person and online.1–5 These treat-
ment options do not differ substantially in
effectiveness,4 6 yet signiﬁcant side effects are
more commonly reported with the use of
antidepressant medications.7 8 While consu-
mers tend to prefer psychosocial therapies,9
75% of consumers use antidepressant medi-
cation and only 43% use psychosocial inter-
ventions.10 In addition, individuals with
depression often do not adhere to treat-
ment,11–14 especially with antidepressants.12–14
While lack of access is an issue for some
treatment options, misalignment between a
consumer’s preferred treatment and pre-
scribed treatment can contribute to low
adherence and is detrimental to the
Strengths and limitations of this study
▪ This study aimed to identify information prior-
ities for consumers and clinicians making
depression treatment decisions via a US national
survey of 972 consumers and 244 clinicians.
▪ To our knowledge, no other study of this scale
has compared the information priorities of con-
sumers and clinicians with regard to depression
treatment decisions.
▪ The convenience sampling approach precludes
true representativeness, though sampling quotas
were in place to approximate the prevalence of
depression among US adults on age and gender
within our sample.
▪ The results from this study can inform the devel-
opment of a decision support intervention to
increase SDM and alignment of information pri-
orities between consumers and clinicians facing
depression treatment decisions.
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therapeutic alliance between consumer and clinician.15
Likewise, aligning treatment decisions with consumer
preferences results in lower rates of treatment attrition,
fewer missed appointments, higher consumer satisfac-
tion and better clinical outcomes.16–18
Shared decision-making (SDM) aims to generate
greater alignment between patient preferences and
chosen treatments with a view to improving subse-
quent treatment outcomes.19 When individuals with
depression are involved in SDM, treatment selection,
adherence, satisfaction and outcomes are
improved.18 20 21 Yet many individuals with depression
experience inadequate SDM. Solberg et al22 surveyed
1168 adults with depression in Minnesota and found
moderate levels of SDM. Consumers who were older,
who were in poverty, who were of poorer general
health or who had been treated for longer than
6 weeks reported lower levels of SDM, although the
generalisability of these results is limited given that all
participants were from a primary care sample.
Additionally, independent raters found very low levels
of SDM across 287 audio-recorded encounters of stan-
dardised patients presenting to primary care practices
with symptoms of depression.23
These low levels of SDM are not surprising: individuals
with depression often are not given time to ask questions
about treatments and are dissatisﬁed with the amount of
information they receive.24 Decision support interven-
tion tools (DESIs) have been suggested as a solution.25
DESIs increase patient knowledge about treatment
options and have the potential to enhance consumer–
clinician communication.26 DESI use has been shown to
help patients develop more informed, preference-led
treatment choices.26 Issue cards, decision boxes and
option grids are examples of brief tools for use during
clinic visits that are shown to increase SDM.27 However,
few DESIs have been designed and tested for
English-speaking patients with depression,28 and those
that focus exclusively on comparing medication options
and do not include evidence about other equally effect-
ive psychosocial treatments.29 To date, only one DESI,
developed and tested in German, includes information
on medication and psychotherapy.30 Early studies of the
existing DESIs are promising, indicating increases in
consumer engagement, satisfaction, knowledge, reduc-
tions in decisional conﬂict and no difference in consult-
ation time.29 30
DESI development requires an understanding of the
information considered important by both healthcare
consumers and healthcare professionals. A search for
previous work addressing this issue did not identify any
relevant studies.
We aimed to address this gap by identifying the infor-
mation most important to consumers and clinicians
when making depression treatment decisions and assess
the extent of SDM in routine depression care as
reported by consumers.
METHODS
Participants
We administered parallel cross-sectional national surveys
between September 2014 and January 2015 to conveni-
ence samples of: (1) individuals who were currently
being treated, were awaiting treatment or had previously
been treated for depression; and (2) clinicians who had
recently treated individuals with depression. Dartmouth
College’s Committee for the Protection of Human
Subjects (CPHS) considered this project exempt from
Institutional Review Board (IRB) review. All surveys were
completed online and hosted by Qualtrics (Qualtrics
LLC, Provo, Utah, USA).
Consumers
Consumers were eligible for inclusion if they had ever
been diagnosed with, counselled about or treated for
depression; were aged 18 years or older; resided in the
USA; and were comfortable reading and writing in
English.
Clinicians
Clinicians were eligible for inclusion if they counselled,
diagnosed or treated a person with depression in the
prior 12 months; practised in the USA; and were com-
fortable reading and writing in English. We deﬁne clin-
ician to include primary care physicians (including
internal and family medicine), psychiatrists, psycholo-
gists, psychiatric/mental health nurses, social workers
and licensed professional counsellors.
Recruitment
Participants were recruited from convenience samples.
Approximately 15 US-based healthcare organisations
and consumer advocacy groups shared a hyperlink to
the survey via email, listserv, social media (Facebook and
Twitter) or personal communication (see online supple-
mentary appendix 1 for details).
To ensure the sample of consumer respondents
matched population distributions, we adopted recruit-
ment quotas based on epidemiological data.31 These
quotas helped to approximate the lifetime prevalence of
depression among US adults with regard to age, gender
and educational attainment. Similar data were not avail-
able for the clinician sample.
We used paid advertising via Facebook to target male
consumers due to low survey uptake. We supplemented
clinician recruitment with respondents from Qualtrics
Panels (Qualtrics LLC, Provo, Utah, USA).
Measures
We developed a 53-item patient survey and a 63-item
clinician survey (see online supplementary appendices 2
and 3). The surveys used a combination of validated,
adapted and newly developed questions (more detail is
provided below). The surveys were informally piloted
with local clinicians, research staff and consumer
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representatives to assess survey duration, ﬂow and ease
of interpretation. Our approach modelled that of a
recent survey investigating what matters most to indivi-
duals facing contraception decisions.32
Patient survey
The patient survey consisted of ﬁve sections: sociodemo-
graphics, health status, treatment experience, informa-
tion priorities and SDM. The information priorities
section consisted of 20 frequently asked questions
(FAQs) deemed pertinent to depression treatment
decision-making based on a literature review of peer-
reviewed journal articles, guidelines, existing decision
support tools for depression and stakeholder input.
Respondents were also given an opportunity to list add-
itional information priorities within the survey.
Sociodemographic questions were based on US Census
items;33–36 questions on health status (comorbidities,
current depression status) and treatment experience
(treatment history, treating clinician) were developed for
this study.
To assess information priorities, consumers were asked
to rate 20 FAQs on a ﬁve-point Likert-type importance
scale in response to the question, ‘How important is
each of these questions to you when choosing a treat-
ment for depression?’ Responses ranged from
‘extremely unimportant’ to ‘extremely important’ with
an additional ‘don’t know what this means’ response
option. FAQs were divided into ﬁve blocks covering four
content areas: the process of receiving treatment, life-
style impact, side effects and ﬁnancial considerations.
The presentation of item blocks and items within blocks
was randomised to avoid order effects. FAQs marked
either important or very important were then included
together on a subsequent webpage and ranked by
respondents to ascertain the top ﬁve information prior-
ities. The same process was followed for side effects:
where ‘side effects’ were marked important or extremely
important, respondents were asked to rank the top 5
from a list of 12 commonly reported side effects.
Consumers were also asked to complete CollaboRATE,
a three-item validated measure of SDM, based on the
most recent clinical encounter where depression was dis-
cussed.37 38 The items are: (1) How much effort was
made to help you understand your health issues? (2)
How much effort was made to listen to the things that
matter most to you about your health issues? (3) How
much effort was made to include what matters most to
you in choosing what to do next? Each of the three
items was rated on a scale of 0 (no effort was made) to 9
(every effort was made).
Clinician survey
The clinician survey consisted of ﬁve sections: sociode-
mographics, practice setting, depression treatment
experience, information priorities and SDM. To assess
information priorities, clinicians followed the same
process as consumers. Clinicians were asked to answer
the questions from two perspectives: (1) their own per-
spective as clinicians (‘In order to treat your patients’
depression, how important do you think it is to discuss
the following questions?’); and (2) the consumer per-
spective (‘In your experience, how important do patients
believe the following questions are when choosing a
treatment for depression?’).
Analysis
We used weighted scores to assess the ﬁve most import-
ant FAQs from each of three perspectives: (1) the consu-
mer’s perspective; (2) the clinician’s personal
perspective; and (3) the clinician’s view of the consumer
perspective.
FAQs within a respondent’s top ﬁve were assigned
weights based on their ranked order. The most import-
ant FAQ received ﬁve points, the second most important
FAQ received four points, and so on, with the ﬁfth most
important FAQ receiving one point. FAQs outside the
top ﬁve did not receive any points as respondents were
asked to rank only their top ﬁve. Overall points per FAQ
were summed and FAQs were rank-ordered; the FAQ
with the most points was considered the most important.
The same weighting procedure was used to rank side
effects. Subgroup analyses of rankings were conducted
by consumer age, gender and educational attainment,
and by clinician practice specialty.
To assess the impact of consumers’ sociodemographic
characteristics and treatment experience on their experi-
ences of SDM, we conducted multiple logistic regression
analysis with CollaboRATE top score as the outcome
variable.38 The highest possible CollaboRATE scores (ie,
27) were coded with a value of ‘1’; all lower scores were
coded ‘0’. We calculated the average predicted probabil-
ity of obtaining a CollaboRATE score adjusting for all
other variables in the model. The top score is a validated
method of scoring CollaboRATE and allows more mean-
ingful interpretation of the score, namely, the propor-
tion of consumers who perceived a highest possible
quality SDM process compared with those who felt there
was some room for improvement.
Individual item analysis used pairwise deletion, while
the regression analysis used listwise deletion. Analyses
were conducted using Stata V.13 (StataCorp LP, College
Station, Texas, USA). All tests were considered statistic-
ally signiﬁcant at p≤0.05.
Sample size
We planned to recruit a sample of 1000 consumers,
which in a similarly sized probability sample would
provide 95% conﬁdence of estimating the population’s
information priorities to within±3%. This also allowed
for a minimum of 10 observations per parameter in the
multiple logistic regression model of CollaboRATE
top scores.39 We targeted a minimum of 30 responses per
clinician specialty and purposefully sought more primary
care physicians than psychiatrists, as approximately 30%
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of all outpatient visits (initial or follow-up) for depressive
disorders occur in primary care.40
RESULTS
Participants
In total, 1557 consumers began the survey, 1096 met all
eligibility criteria and 972 attempted to answer survey
questions. For the 972 consumers who attempted survey
questions, median completion time was 12 min. Five
consumers spent longer than 24 h on the survey. In
total, 471 clinicians began the survey, of whom 300
met all eligibility criteria and 244 attempted to answer
survey questions. Clinicians’ median completion time
was 11 min, with one clinician spending longer than
24 h on the survey.
The sociodemographic proﬁle of consumer respon-
dents (table 1) approximated lifetime prevalence of
major depressive disorder in the USA on age and
gender.31 Consumer respondents were mostly female
(n=664/967; 69%), Caucasian (n=716/776; 92%) and
covered a diverse range of ages (mean 43.17, SD 13.41).
Many had comorbid anxiety disorders (n=649/953;
67%) and a majority had at least some postsecondary
education (n=615/786; 79%).
Consumer respondents were predominantly still in
treatment (n=756/972; 78%) and reported their princi-
pal clinicians to be therapists (n=338/968; 35%), psy-
chiatrists (n=327/968; 34%) or primary care physicians
(n=235/968; 24%). Antidepressants were the most
common treatment used (n=901/970; 93%), with talk
therapy (n=703/970; 72%) and lifestyle changes
(n=412/970; 42%) also commonly reported (table 2).
Clinician respondents were distributed across a
variety of clinical specialties, with therapists (n=109/
Table 1 Demographic profile of consumer respondents
Characteristic
Number of
consumers (%)
Age, years n=972
18–29 185 (19)
30–39 203 (21)
40–49 249 (26)
50–59 221 (23)
60–69 98 (10)
70+ 16 (2)
Gender n=967
Female 664 (69)
Male 295 (31)
Other 8 (1)
Education n=786
Less than college 162 (21)
Some college/college degree 465 (59)
Graduate/professional degree 150 (19)
Prefer not to say 9 (1)
Employment status n=740
Employed 422 (57)
Not employed 318 (43)
Marital status n=740
Married 297 (40)
Single (never married) 234 (32)
Separated or divorced 179 (24)
Widowed 12 (2)
Prefer not to say 18 (2)
Community environment (residence) n=742
Urban/metropolitan (50 000 +) 358 (48)
Large rural city/micropolitan
(10 000–49 999)
169 (23)
Small rural city/town (2500–9999) 170 (23)
Isolated rural town (under 2500,
60+min to urban area)
45 (6)
Race* n=776
White 716 (92)
American Indian or Alaska Native 33 (4)
African-American 28 (4)
Asian 9 (1)
Native Hawaiian or Pacific Islander 3 (0)
Other 27 (3)
Ethnicity n=768
Not Hispanic/Latino 719 (94)
Hispanic/Latino 49 (6)
Language spoken at home n=964
English 901 (93)
Other 63 (7)
Health insurance status n=742
Insured through my current or
former employer
233 (31)
Insured through a family member’s
current or former employer
161 (22)
Insured through a public
programme (eg, Medicare,
Medicaid, CHIP)
158 (21)
Insured through a government
exchange
29 (4)
Insured directly from an insurance
company
27 (4)
Continued
Table 1 Continued
Characteristic
Number of
consumers (%)
Not insured 88 (12)
Other 28 (4)
Prefer not to say 18 (2)
Mental health comorbidities* n=953
Anxiety disorder 649 (68)
Post-traumatic stress disorder 285 (30)
Obsessive-compulsive disorder 145 (15)
Other 466 (49)
None 133 (14)
Other long-term health conditions* n=925
Hypertension 82 (9)
Diabetes/prediabetes 78 (8)
Arthritis 41 (4)
Asthma 38 (4)
Fibromyalgia 34 (4)
Other 442 (48)
None 513 (55)
*Multiple selections allowed.
CHIP, Children’s Health Insurance Program.
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244; 45%), primary care physicians (n=81/244; 33%),
psychiatrists (n=25/244; 10%) and other clinicians
(n=29/244; 11%) represented (table 3). On average,
clinician respondents had 15.08 years professional
experience (SD 10.96). All had treated individuals for
depression in the past year, with 90% reporting that at
least a substantial portion of their clients has depres-
sion. Combination therapy (n=75/241; 31%), talk
therapy (n=75/241; 31%) and antidepressant medica-
tions (n=65/241; 27%) were clinicians’ most frequent
treatment approaches. Primary care practitioner (PCPs)
made more frequent use of antidepressant medications
than did other clinician types. When comparing
prescribers (PCPs and psychiatrists) to non-prescribers
(therapists), prescribers say they most often request
antidepressants alone (55%) followed by combination
therapy (33%) and talk therapy (3%), while non-
prescribers instead favour talk therapy (59%) and com-
bination therapy (34%) over solely medication (1%).
What matters most in treatment decision-making
Consumer perspective
The 742 consumers who answered ranking questions
felt the most important information when making a
treatment decision was ‘Will the treatment work?’, fol-
lowed by ‘What are the side effects of this treatment?’,
‘Is the treatment covered by insurance?’, ‘How long
before I feel better?’ and ‘How much does this treat-
ment cost?’ (table 4). Consumers’ most concerning
potential side effect was increased risk of suicide,
followed by sleep issues, weight change, heart
problems and increased stress (see online supplemen-
tary appendix 4).
Importance rankings did not show evidence of vari-
ation by consumer age, gender or educational attain-
ment (analysis available on request).
Clinician perspective: What consumers need to know
Two hundred and two clinicians completed rankings of
what they perceived to be most important in depression
treatment decisions. When considering the information
priorities from their professional perspectives, clinicians
Table 2 Demographic profile of clinician respondents
Characteristic
Number of
clinicians (%)
Specialty n=244
Therapist* 109 (45)
Primary care/internal medicine
physician
81 (33)
Psychiatrist 25 (10)
Psychiatric/mental health nurse 6 (3)
Other 23 (9)
Proportion of past year’s clients with
depression
n=243
A majority 67 (28)
A substantial portion 151 (62)
Few 25 (10)
Preferred treatment n=241
Combination talk therapy and
medication
75 (31)
Talk therapy 75 (31)
Antidepressant medication 65 (27)
Lifestyle changes 18 (7)
Alternative therapy 6 (2)
Electroconvulsive therapy 2 (1)
Community environment (workplace) n=205
Urban/metropolitan (50 000+) 84 (41)
Large rural city/micropolitan
(10 000–49 999)
53 (26)
Small rural city/town (2500–9999) 61 (30)
Isolated rural town (under 2500,
60+min to urban area)
7 (3)
Race† n=204
White 179 (88)
Asian 18 (9)
African-American 6 (3)
American Indian or Alaska Native 4 (2)
Native Hawaiian or Pacific Islander 0 (0)
Other 1 (0)
Ethnicity n=203
Not Hispanic/Latino 194 (96)
Hispanic/Latino 9 (4)
Language spoken at home n=243
English 212 (87)
Other 31 (13)
*‘Therapist’ describes non-prescribing clinicians including
psychologist, social worker and licensed professional counsellor.
†Multiple selections allowed.
Table 3 Consumer treatment experience
Characteristic
Number of
consumers (%)
Treatment status n=972
Currently in treatment 756 (78)
Treated in the past 169 (17)
Awaiting treatment 47 (5)
Primary treating clinician n=968
Therapist or psychologist 338 (35)
Psychiatrist 327 (34)
Primary care doctor 235 (24)
Other 47 (5)
Not sure 21 (2)
Most recent consultation about
depression
n=789
Less than a week ago 183 (23)
1 week to 1 month ago 222 (28)
1–6 months ago 214 (27)
6–12 months ago 60 (8)
12 or more months ago 110 (14)
Treatments used (lifetime)* n=970
Antidepressant medication 901 (93)
Talk therapy 703 (72)
Lifestyle changes 412 (42)
Alternative therapy 141 (15)
Electroconvulsive therapy 46 (5)
Deep brain stimulation 9 (1)
*Multiple selections allowed.
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ranked ‘Will the treatment work?’ ﬁrst, followed by
‘How long before the patient feels better?’, ‘What are the
side effects of this treatment?’, ‘How does the treatment
work?’ and ‘What is involved in using the treatment?’
(table 4). These information priorities diverged from
those of consumers in the area of cost and insurance
coverage.
Slight differences in information priority rankings by
clinician type are outlined in online supplementary
appendix 5. PCPs and psychiatrists ranked ‘Will this
treatment affect other existing health conditions?’
much higher than therapists. Psychiatrists and therapists
ranked ‘What is involved in using this treatment?’
higher than PCPs, while ‘How much does the treat-
ment cost?’ was ranked higher by PCPs than by psychia-
trists or therapists. The most concerning potential side
effect for clinicians was increased risk of suicide, fol-
lowed by drug–drug interactions, heart problems,
weight change and sexual issues (see online supple-
mentary appendix 2).
Clinician perspective: What consumers want to know
One hundred and seventy-two clinicians completed
rankings of what they believe their clients ﬁnd most
important when making a treatment decision. When
considering the importance of the information priorities
from a consumer’s perspective, clinicians included the
same priorities as consumers but in a different order
(table 4). ‘Will the treatment work?’ again ranked
number 1, followed by ‘How long before the patient
feels better?’, ‘How much does the treatment cost?’, ‘Is
the treatment covered by insurance?’ and ‘What are the
side effects of this treatment?’. No evidence was found
for signiﬁcant differences by clinician type (see online
supplementary appendix 4).
Engagement in care
Only 18% (n=144/781) of consumers reported a
CollaboRATE top score, indicating that a majority of
consumer respondents perceived low levels of SDM in
their most recent clinical encounters. Many consumers
(n=405/789; 51%) had their most recent visits within
the previous month (table 2).
CollaboRATE top scores were more likely where the
respondents were female (OR 2.14, p=0.003) or where
they worked with a psychiatrist (OR 1.91, p=0.025;
table 5). Respondents in older age groups appeared
more likely to report a CollaboRATE top score com-
pared with those under 30 years old, with statistically sig-
niﬁcant associations found in the 40–49 years old and
over 60 years old groups (table 5). Yet when age was ana-
lysed as a continuous variable, no association between
age and CollaboRATE top score was found (analysis
available on request). The probability of a CollaboRATE
top score where a consumer worked with a psychiatrist
was 24.5% (95% CI 18.7% to 30.3%), 18.5% when
working with a therapist (95% CI 13.4% to 23.6%) and
14.8% when working with a primary care physician
(95% CI 8.9% to 20.7%). The predicted probability of
females reporting a CollaboRATE top score was 22.0%
(95% CI 18.2% to 25.9%) compared with males, 12.2%
(95% CI 7.4% to 16.9%).
DISCUSSION
The information priorities of individuals with depression
in the USA are not always aligned with those of clini-
cians. Consumers and clinicians agree that effectiveness
of treatment, side effects and speed of recovery are
important. While treatment costs and insurance cover-
age are a higher priority for consumers, explanations of
how a treatment should be used and how it works were
more important for clinicians. However, when clinicians
were asked to adopt a consumer perspective, they were
able to reliably report what consumers view to be most
important. For side effect rankings, there was close align-
ment between consumers and clinicians; however, unlike
clinicians, consumers included sleep issues and
increased stress related to treatment among the most
Table 4 Top five information priorities
Information priority
Weighted
score N
Clinicians, from clinician perspective
#1 Will the treatment work? 566
#2 How long before the
patient feels better?
348
#3 What are the side effects
of this treatment?
318
#4 How does the treatment
work?
242
#5 What is involved in using
the treatment?
224
Total 202
Clinicians, from patient perspective
#1 Will the treatment work? 469
#2 How long before the
patient feels better?
380
#3 How much does the
treatment cost?
266
#4(tie) Is the treatment covered
by insurance?
232
#4(tie) What are the side effects
of this treatment?
232
Total 172
Patients
#1 Will the treatment work? 1524
#2 What are the side effects
of this treatment?
1407
#3 Is the treatment covered
by insurance?
1224
#4 How long before I feel
better?
1147
#5 How much does this
treatment cost?
984
Total 782
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concerning side effects. A lack of SDM observed in the
context of depression treatment decisions may explain
this misalignment in information priorities.
Interpretation of findings
This is the ﬁrst study to identify and compare consu-
mers’ and clinicians’ information priorities when consid-
ering depression treatment decisions. It is reassuring to
ﬁnd alignment in several areas and promising to observe
that clinicians are aware of consumer information prior-
ities. However, clinicians do not prioritise insurance and
cost information, despite realising its importance to con-
sumers. The importance of cost and insurance informa-
tion to consumers is consistent with previous
literature.41 42 The low priority we found clinicians give
to cost and insurance coverage information supports
previous research on frequency of clinician–consumer
communication about out-of-pocket costs.43 This lack of
communication has been attributed to time limitations
within clinical encounters, the challenge of identifying
consumer-speciﬁc costs, and a belief that medical deci-
sions should be based exclusively on needs, not
costs.44 45 Yet the cost of treatment has a signiﬁcant
impact on consumer well-being, ﬁnancial stability, adher-
ence and eventual health status.46
In contrast to other studies across many conditions47 48
where CollaboRATE scores average around 70%, only
18% of individuals with depression reported a top score
on CollaboRATE. Our ﬁndings support previous studies
where consumers with depression report low SDM in
primary care and extend this result to other clinical spe-
cialties.22 23 Female consumers were more likely to
report higher CollaboRATE scores. This may be
explained by previous research indicating females’ pref-
erence for more active roles in decision-making.49 While
SDM was low across all clinician types, primary care phy-
sicians scored signiﬁcantly lower than psychiatrists.
These low scores may result from additional time pres-
sures, as Tai-Seale et al 50 reported that a sample of
primary care clinicians treating patients with mental
health needs spent on average only 2 min per visit on
mental health issues. Despite these differences in
CollaboRATE scores by clinician type, we can conclude
that consumers generally perceived low levels of SDM.
Table 5 Analysis of CollaboRATE top scores
Unadjusted
regression
Adjusted
regression
OR (95% CI) OR (95% CI)
Unadjusted
proportion (n)
Adjusted predicted
proportion (95% CI)
Clinician most frequently seen
Primary care physician 1.00 (reference) 1.00 (reference) 14% (25) 15 (9 to 21)
Psychiatrist 1.80 (1.08 to 3.00) 1.87 (1.07 to 3.26) 23% (62) 24 (19 to 30)
Therapist 1.39 (0.82 to 2.34) 1.31 (0.73 to 2.34) 19% (51) 19 (13 to 24)
Other/not sure 0.72 (0.28 to 1.87) 0.80 (0.30 to 2.13) 11% (6) 12 (3 to 21)
Age
18–29 1.00 (reference) 1.00 (reference) 13% (19) 13 (7 to 19)
30–39 1.82 (0.99 to 3.35) 1.85 (0.96 to 3.54) 21% (34) 21 (14 to 28)
40–49 2.26 (1.26 to 4.03) 2.10 (1.11 to 3.97) 24% (48) 23 (17 to 30)
50–59 1.09 (0.58 to 2.09) 1.24 (0.62 to 2.48) 14% (24) 15 (9 to 21)
60+ 2.05 (1.01 to 4.13) 2.49 (1.14 to 5.43) 23% (19) 27 (16 to 37
Treatments used
Antidepressant medication only 1.00 (reference) 1.00 (reference) 12% (14) 14 (7 to 22)
Medication and other treatment 1.92 (1.06 to 3.46) 1.52 (0.80 to 2.91) 20% (124) 20 (17 to 24)
Non-medication treatment 0.99 (0.36 to 2.74) 0.93 (0.29 to 3.00) 12% (6) 13 (2 to 25)
Gender
Male 1.00 (reference) 1.00 (reference) 12% (25) 12 (7 to 17)
Female 2.00 (1.26 to 3.18) 2.04 (1.24 to 3.34) 21% (119) 22 (18 to 26)
Treatment status
Currently being treated 1.00 (reference) 1.00 (reference) 19% (118) 19 (15 to 22)
Awaiting treatment 0.87 (0.35 to 2.14) 0.93 (0.33 to 2.62) 17% (6) 18 (3 to 33)
Treated in the past 0.78 (0.47 to 1.32) 0.98 (0.56 to 1.71) 16% (20) 19 (11 to 26)
Education level
High school or less 1.00 (reference) 1.00 (reference) 20% (31) 22 (15 to 29)
Some college to Bachelor’s degree 0.93 (0.59 to 1.47) 0.77 (0.47 to 1.27) 19% (85) 18 (14 to 22)
Graduate/professional degree 0.96 (0.54 to 1.69) 0.77 (0.42 to 1.44) 19% (28) 18 (11 to 25)
Health insurance status
Private health insurance 1.00 (reference) 1.00 (reference) 19% (86) 19 (15 to 23)
Public health insurance 1.22 (0.78 to 1.90) 1.06 (0.66 to 1.71) 23% (35) 20 (13 to 26)
No insurance 0.88 (0.48 to 1.61) 0.89 (0.47 to 1.69) 17% (15) 17 (9 to 25)
Bold typeface indicates significance level of p<0.05.
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Strengths and limitations
Though our convenience sampling approach eliminates
conﬁdentiality concerns associated with preidentifying
individuals with depression across the USA, we are as a
result unable to determine response rates and lack true
representativeness; a probability sample would address
this concern. However, by ensuring that the respondent
sample approximated epidemiological data on lifetime
depression prevalence with regard to age and gender,
we reduced the potential impact of selection bias. In
addition, clinicians in our survey are likely to treat a
broad spectrum of individuals with depression; there-
fore, a wide range of consumers inform their views of
what is most important to consumers. That these views
match the views prioritised by the consumer sample is
reassuring. As we were unable to target clinician sam-
pling due to a lack of relevant data, the potential for
selection bias remains a concern.
Additionally, independent clinician and consumer
samples preclude direct comparisons between the
groups. Further research is needed to address conver-
gence or divergence of information priorities within
clinician–consumer dyads. However, broad inclusion cri-
teria for consumers and clinicians enabled thorough
representation of depression care in the USA, evident by
consumer responses from 49 of 50 US states and the
District of Columbia.
Implications
While clinicians are aware of what matters most to con-
sumers with depression, they do not always prioritise this
information. Low SDM combined with a misalignment
in information priorities between consumers and clini-
cians may explain why consumers often do not receive
their preferred treatments.51
Better equipping clinicians to talk to consumers about
information central to consumer decision-making, such
as the cost and insurance coverage associated with differ-
ent treatment options, can lead to more engaged and
empowered consumers. This is of particular interest
given the expansion of mental health coverage and
depression screening resulting from the Patient
Protection and Affordable Care Act. Despite previous
research ﬁnding an association between SDM and
higher consumer satisfaction in depression care,21
routine clinician training in SDM is still lacking. The
current work can help inform development of a DESI
for depression that consists of key information priorities
identiﬁed by consumers and clinicians. These tools have
demonstrated promise in treating other conditions and
may help facilitate clinician–consumer conversations in
depression care, leading to better informed consumers
choosing treatments that are right for them. We are
currently in the process of developing a DESI based on
our ﬁndings and testing understanding, comprehensive-
ness and acceptability with key stakeholders (consumers,
general public and clinicians) through cognitive
interviews.
CONCLUSION
While consumers and clinicians agreed on some infor-
mation priorities for depression treatment decision-
making, there was misalignment in the area of treatment
cost and insurance coverage despite clinician awareness
of the importance of these issues to consumers. The low
levels of SDM reported by consumers with depression
emphasise the impact of this priority mismatch. Future
work on interventions to improve depression treatment
decision-making may help narrow the existing gap
between consumers’ and clinicians’ information prior-
ities and increase SDM, leading to treatments aligned
with consumer preferences.
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